Nxera Pharma Licenses Lucerastat Rights in APAC for CHF 7M Upfront
Nxera exercised its option to license lucerastat from Idorsia, securing exclusive rights in Japan, South Korea, Taiwan and select APAC markets outside China. It will pay CHF 7 million upfront and contribute to the global Phase 3 program.
Nxera exercised its option to license lucerastat from Idorsia, gaining exclusive rights in Japan, South Korea, Taiwan and select APAC markets (ex-China), paying CHF 7M upfront and contributing to the global Phase 3 program.Material DetailsContext by AI AnalystStrategic expansion adds a late-stage…